BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in utilizing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology. The firm offers IGALMI, a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults. It also develops BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of prostate cancer and solid tumors that are refractory to checkpoint inhibitors. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

BioXcel Therapeutics Reports Successful Q1 2023, Anticipates Market Expansion

BioXcel Therapeutics had a successful Q1 2023, with a focus on commercial progress and upcoming clinical milestones. The company is confident in its strategic financing and revenue expectations, while also exploring opportunities for market expansion and growth through its lead neuropsychiatric program and subsidiary, Onco Xcel Therapeutics.

BioXcel Therapeutics reprioritizes drug candidates amidst workforce reduction and positive trial results

BioXcel Therapeutics is navigating challenges stemming from investigator misconduct and workforce reduction while prioritizing AI-driven innovation and drug development. Positive top-line data from trials and ongoing discussions with the FDA demonstrate progress, and the company is exploring market access and potential partnerships for growth.

BTAI reports Q3 net revenue of $341,000, secures strategic financing

BTAI's Q3 2023 performance reflects ongoing investment in research and development, with a focus on late-stage clinical programs. The company has secured additional financing options and is strategically positioned to explore market opportunities and address safety considerations for at-home trials.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

New York, New York--(Newsfile Corp. - April 16, 2021) - Levi & Korsinsky announces it has commenced an investigation of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/bioxcel-therapeutics-inc-information-request-form or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of BioXcel Therapeutics, Inc. (BTAI)

Investors were not impressed with the biotech's latest clinical update.

Why BioXcel Therapeutics Stock Is Plunging Today

BioXcel Therapeutics Inc (NASDAQ: BTAI) has announced topline results from its Phase 1b/2 proof-of-concept RELEASE study evaluating BXCL501 for the treatment of opioid withdrawal symptoms. BXCL501 is the Company's proprietary, orally dissolving thin film formulation of dexmedetomidine.

BioXcel Stock Is Trading Lower After BXCL501 Data In Opioid Withdrawal Study

Primary safety endpoint achieved in first study of BXCL501 dosed twice-daily over seven days

BioXcel Therapeutics Announces Results of Phase 1b/2 Study of BXCL501 for the Treatment of Opioid Withdrawal Symptoms

The FDA has designated Breakthrough Therapy status to BioXcel Therapeutics Inc's (NASDAQ: BTAI) BXCL501, to treat agitation associated with dementia. The designation intends to expedite the development and review of certain product candidates.

FDA Gives Accelerated Review Tag To BioXcel's BXCL501 In Dementia-Related Agitation

Designation offers the potential for expedited development and review, highlighting the urgent need for new treatment options for dementia related agitation Designation offers the potential for expedited development and review, highlighting the urgent need for new treatment options for dementia related agitation

BioXcel Therapeutics Receives FDA Breakthrough Therapy Designation for BXCL501 for the Acute Treatment of Agitation Associated with Dementia

BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q4 2020 Results - Earnings Call Transcript

New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

We revisit BioXcel Therapeutics in-depth for the first time in five months. The company has seen several encouraging developments on the pipeline front and continues to receive favorable analyst commentary.

Still Betting On BioXcel Therapeutics Stock

NEW HAVEN, Conn., March 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Thursday, March 11, 2021 at 8:30 AM Eastern Time to discuss its fourth quarter and full year 2020 operating and financial results.

BioXcel Therapeutics to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call and Webcast

BioXcel Therapeutics Inc (NASDAQ: BTAI) plans to finalize study design, dosing, and endpoints for its BXCL501 Phase 3 program in dementia-related agitation. The end of the Phase 2 meeting with the FDA is scheduled in Q2 2021.

BioXcel's BXCL501 Lower Dose Shows Statistical Significance On Agitation Scales

Review of TRANQUILITY data show ed 30 mcg dose met statistical significance across multiple scales

BioXcel Therapeutics Provides Update on its BXCL501 Program for the Acute Treatment of Dementia Related Agitation

Former Allergan executive brings extensive global regulatory experience across multiple therapeutic areas Former Allergan executive brings extensive global regulatory experience across multiple therapeutic areas

BioXcel Therapeutics Appoints June Bray to Board of Directors

BioXcel Therapeutics Inc (NASDAQ: BTAI) initiated the Phase 2 PLACIDITY trial evaluating BXCL501 to treat delirium-related agitation. The 20 subject-trial is designed to evaluate the safety, efficacy, and pharmacokinetics of BXCL501 in intensive care unit adult patients experiencing delirium-related agitation, including COVID-19 patients.

BioXcel Therapeutics Starts Testing BXCL501 In Mid-Stage Delirium-Related Agitation Study

NEW HAVEN, Conn., Feb. 23, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of Javier Rodriguez as Senior Vice President, Chief Legal Officer and Corporate Secretary, effective immediately. Mr. Rodriguez will report to Chief Executive Officer, Vimal Mehta and joins BioXcel with 20 years of extensive strategic and legal experience within the biopharmaceutical industry.

BioXcel Therapeutics Appoints Javier Rodriguez as Chief Legal Officer and Corporate Secretary

Live webcast to be held on February 19th from 11:00 am ET to 2:00 pm ET Live webcast to be held on February 19th from 11:00 am ET to 2:00 pm ET

BioXcel Therapeutics to Host Virtual Key Opinion Leader Event to Highlight BXCL501 as a Potential Treatment for Agitation and Opioid Withdrawal Symptoms

NEW HAVEN, Conn., Feb. 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that an update from its ongoing Phase 1b/2 trial of BXCL701, the Company's investigational, oral innate immunity activator, in aggressive forms of prostate cancer will be presented in a poster session at the virtual 2021 ASCO Genitourinary ("ASCO GU") Cancers Symposium. ASCO GU is being held from Thursday, February 11, 2021 to Saturday, February 13, 2021.

BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium

A Wall Street analyst has high hopes for the company.

Why BioXcel Therapeutics Stock Popped Today

Rada Electronic

Teladoc

XPeng

High-growth names with positive catalysts that can outperform the markets make these some of the best investments to start 2021. The post 4 of the Best Investments to Start 2021 appeared first on InvestorPlace.

4 of the Best Investments to Start 2021

BioXcel uses a proprietary AI program to screen for ways to repurpose old drugs and screen for useful biomarkers that can allow for faster, safer, and cheaper drug development. BioXcel's lead asset BXCL501 is targeting a broad swath of agitation-related indications that could be very lucrative for the company.

BioXcel Therapeutics Has Compelling Upside Potential In Advance Of Multiple Data Readouts

Company to present corporate update and plans for 2021

BioXcel Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Grant will support clinical studies in patients with post-traumatic stress disorder related to alcohol and substance abuse Grant will support clinical studies in patients with post-traumatic stress disorder related to alcohol and substance abuse

BioXcel Therapeutics Announces Grant by U.S. Department of Defense to Evaluate BXCL501 in Patients Suffering from PTSD

NEW HAVEN, Conn., Nov. 13, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference.

BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference

BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q3 2020 Results - Earnings Call Transcript

Complete NDA submission for BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorders on track for Q1 2021

News for BioXcel Therapeutics Stock (BTAI)